Drugs / Trabedersen
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06579196 | May 2025 → Mar 2028 expected | non-small cell lung carcinoma | University of Nebraska | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05935774 | Dec 2023 → Jul 2028 | non-small cell lung carcinoma | University of Washington | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT00761280 | Dec 2008 → Feb 2012 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-07-17 | Mateon Therapeutics | Results Oncotelic Therapeutics Highlights Peer Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients oncotelic.com ↗
Clinical data from the OT 101 P001 PDAC study suggest that targeting TGFB2 merits additional evaluation in younger patients; in a treated subset characterized by low IL 6, median OS was 12.7 months. |
| 2024-06-11 | Mateon Therapeutics | Results ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY oncotelic.com ↗
High AUC exhibited a doubling of PFS to 84 days versus 40 days. |
| 2022-07-12 | Mateon Therapeutics | Results Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer oncotelic.com ↗
Among those who underwent subsequent chemotherapy, high AUC was associated with improved OS, 9.6 vs. 2.4 mos, p=0.0006 |
| 2022-06-15 | Mateon Therapeutics | Results Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention oncotelic.com ↗
OT-10 treatment of high- risk COVID patients reduced mortality from 100% to 50%, p=0.003. |
| 2021-11-16 | Mateon Therapeutics | Results Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers oncotelic.com ↗
In the safety cohort treated during the Trial, the standard dosage of 140mg/m2 of OT-101was well tolerated in combination with IL-2, which has allowed for ongoing dose escalation to 190 mg/m2. |
| 2021-04-19 | Mateon Therapeutics | Results ONCOTELIC THERAPEUTICS, INC. ANNOUNCED SYNERGY BETWEEN OT-101 AND IL-2 (PROLEUKIN) AT AACR-2021 oncotelic.com ↗
TGF-β inhibitor (Trabedersen) and low dose IL-2 (Proleukin) combination treatment is expected to be an effective regimen in solid cancer treatment than individual treatment by alteration of tumor environment. |
| 2019-12-02 | Mateon Therapeutics | Results Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen oncotelic.com ↗
In a completed Phase 2 clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and partial responses in recurrent and refractory adult high-grade glioma patients, including adults with GBM. |
| 2019-11-18 | Mateon Therapeutics | Results Mateon Therapeutics to Present New and Updated Data for OT101 (Trabedersen) Activity Against Brain Tumors at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting oncotelic.com ↗ |
| 2019-09-23 | Mateon Therapeutics | Regulatory FDA Grants Pediatric Disease Designation for Mateon oncotelic.com ↗
Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation for OT101/Trabedersen for the treatment of diffuse intrinsic pontine glioma (DIPG) as a drug for a "rare pediatric disease." |
All press releases naming this drug 27 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trabedersen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00761280 ↗ |
| Known as | OT-101 | “Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).” NCT06579196 ↗1“trabedersen (OT-101) in combination with atezolizumab” NCT05935774 ↗ |
| Action | Inhibit | “specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2)” NCT06579196 ↗ |
| Modality | Antisense oligonucleotide | “a phosphorothioate antisense oligodeoxynucleotide” NCT00761280 ↗ |
| Route | Other | “which is applied intratumorally” NCT00761280 ↗ |
| Target | TGFB2 | “specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2)” NCT06579196 ↗ |